UBS MSCI United Kingdom UCITS ETF(hedged EUR)A-acc is a equity ETF from UBS tracking the UBS Lux Fund Solutions – MSCI United Kingdom index through physical replication. Domiciled in Luxembourg and launched in 2020, the fund manages about 578 M € and charges a TER of 0.20% — 20 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
UBS MSCI United Kingdom UCITS ETF(hedged EUR)A-acc competes with 3 other products on the same index (UBS Lux Fund Solutions – MSCI United Kingdom): it ranks 2nd by fund size and 1st by ongoing cost, with a TER of 0.20% against a group median of 0.20%. It has been listed since 2020, 6 years of track record.
On a €10,000 investment the TER costs 20 € a year. The cheapest of the group is UBS MSCI United Kingdom UCITS ETF(GBP)A-acc at 0.20%, or 20 € on the same amount: a difference of 0 € every year, roughly 0 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 52.9% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR and is a currency-hedged share class: the hedge aims to neutralise the effect of the underlying currencies against the reference currency, at an implicit cost that varies with interest-rate differentials.
The fund is domiciled in Luxembourg, which determines the tax treatment of income received by the fund and the supervisory authority.
| HSBC Holdings PLC | 10.5% |
| AstraZeneca PLC | 9.1% |
| Shell plc | 7.1% |
| Rolls-Royce Holdings PLC | 5.2% |
| Unilever PLC | 4.2% |
| British American Tobacco PLC | 4.0% |
| GSK plc | 3.4% |
| Rio Tinto PLC | 3.3% |
| BP PLC | 3.1% |
| Barclays PLC | 3.0% |
| Borsa Italiana | UKE | EUR |
| XETRA | UFMB | EUR |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.